[go: up one dir, main page]

PA8435201A1 - Derivados 6,6- o 6,7-biciclicos sustituidos que contienen pirido o pirimido. - Google Patents

Derivados 6,6- o 6,7-biciclicos sustituidos que contienen pirido o pirimido.

Info

Publication number
PA8435201A1
PA8435201A1 PA19978435201A PA8435201A PA8435201A1 PA 8435201 A1 PA8435201 A1 PA 8435201A1 PA 19978435201 A PA19978435201 A PA 19978435201A PA 8435201 A PA8435201 A PA 8435201A PA 8435201 A1 PA8435201 A1 PA 8435201A1
Authority
PA
Panama
Prior art keywords
pirimido
pirido
derivatives
substituted
bicycles containing
Prior art date
Application number
PA19978435201A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8435201A1 publication Critical patent/PA8435201A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA I EN LA QUE A, B, D, E, K, G, Z, R3 Y R5 SE DEFINE EN LA MEMORIA, Y A LAS SALES FARMACEUTICAMENTE ACEPTABLES DE DICHOS COMPUESTOS.
PA19978435201A 1996-08-06 1997-08-05 Derivados 6,6- o 6,7-biciclicos sustituidos que contienen pirido o pirimido. PA8435201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2345396P 1996-08-06 1996-08-06

Publications (1)

Publication Number Publication Date
PA8435201A1 true PA8435201A1 (es) 1999-12-27

Family

ID=21815208

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978435201A PA8435201A1 (es) 1996-08-06 1997-08-05 Derivados 6,6- o 6,7-biciclicos sustituidos que contienen pirido o pirimido.

Country Status (40)

Country Link
US (1) US6492520B1 (es)
EP (1) EP0920429B1 (es)
JP (1) JP3345021B2 (es)
KR (1) KR20000029843A (es)
CN (1) CN1093130C (es)
AP (1) AP1096A (es)
AR (1) AR008829A1 (es)
AT (1) ATE232863T1 (es)
AU (1) AU709203B2 (es)
BG (1) BG103143A (es)
BR (1) BR9710808A (es)
CA (1) CA2262692C (es)
CO (1) CO4900060A1 (es)
CZ (1) CZ292806B6 (es)
DE (1) DE69719193T2 (es)
DK (1) DK0920429T3 (es)
DZ (1) DZ2289A1 (es)
EA (1) EA003188B1 (es)
ES (1) ES2191183T3 (es)
GT (1) GT199700089A (es)
HR (1) HRP970432B1 (es)
ID (1) ID17980A (es)
IL (1) IL128188A0 (es)
IS (1) IS4948A (es)
MA (1) MA24296A1 (es)
NO (1) NO313293B1 (es)
NZ (1) NZ333727A (es)
OA (1) OA10970A (es)
PA (1) PA8435201A1 (es)
PE (1) PE97098A1 (es)
PL (1) PL331602A1 (es)
SA (1) SA97180334A (es)
SK (1) SK14099A3 (es)
TN (1) TNSN97135A1 (es)
TR (1) TR199900228T2 (es)
TW (1) TW550265B (es)
UY (1) UY24655A1 (es)
WO (1) WO1998005661A1 (es)
YU (1) YU5399A (es)
ZA (1) ZA976954B (es)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DE69917296T2 (de) 1998-08-20 2005-05-25 Smithkline Beecham Corp. Neue substituierte triazolverbindungen
IL143105A0 (en) 1998-11-12 2002-04-21 Neurocrine Biosciences Inc Fused polycyclic heterocyclic compounds and pharmaceutical compositions containing the same
KR20010080990A (ko) 1998-11-12 2001-08-25 추후기재 Ｃｒｆ 수용체 길항제 및 그와 관련된 방법
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
WO2001058489A1 (en) * 2000-02-14 2001-08-16 Japan Tobacco Inc. Preventives/remedies for postoperative stress
WO2001062718A1 (en) * 2000-02-25 2001-08-30 Japan Tobacco, Inc. Benzamide derivative and use thereof
AR030053A1 (es) * 2000-03-02 2003-08-13 Smithkline Beecham Corp 1h-pirimido [4,5-d] pirimidin-2-onas y sales, composiciones farmaceuticas, uso para la fabricacion de un medicamento y procedimiento para producirlas
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
GB0011964D0 (en) 2000-05-18 2000-07-05 Suyal N Thick glass films with controlled refractive indices and their applications
EP2404603A1 (en) 2000-10-23 2012-01-11 Glaxosmithkline LLC Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
HUP0402310A2 (hu) 2001-09-26 2005-02-28 Bayer Pharmaceuticals Corporation 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
FR2846657B1 (fr) * 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
WO2004056807A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
CN1984660B (zh) 2003-07-03 2010-12-15 美瑞德生物工程公司 作为天冬氨酸特异性半胱氨酸蛋白酶活化剂和细胞程序死亡诱导剂的4-芳基氨基-喹唑啉
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US20050085479A1 (en) * 2003-08-27 2005-04-21 Pharmacia Corporation Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury
JP4790703B2 (ja) * 2004-04-07 2011-10-12 武田薬品工業株式会社 環式化合物
WO2005111024A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
CA2564199A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
MXPA06013164A (es) 2004-05-14 2007-02-13 Pfizer Prod Inc Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal.
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
AR053450A1 (es) * 2005-03-25 2007-05-09 Glaxo Group Ltd Derivados de 3,4-dihidro-pirimido(4,5-d)pirimidin-2-(1h)-ona 1,5,7 trisustituidos como inhibidores de la quinasa p38
PE20061351A1 (es) * 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
JP2008535822A (ja) * 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
EP1865959A2 (en) 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
PT1888548E (pt) 2005-05-26 2012-10-30 Neuron Systems Inc Derivado de quinolina para o tratamento de doenças da retina
EP2345652A1 (en) 2005-12-21 2011-07-20 Abbott Laboratories Antiviral compounds
DE602006015861D1 (de) 2005-12-21 2010-09-09 Abbott Lab Antivirale verbindungen
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
ES2378473T3 (es) 2005-12-21 2012-04-12 Abbott Laboratories Compuestos antivirales
RU2441010C2 (ru) * 2005-12-21 2012-01-27 Эбботт Лэборетриз Противовирусные соединения
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
TW201639852A (zh) 2008-12-09 2016-11-16 吉李德科學股份有限公司 用於製備可用作類鐸受體調節劑之化合物的中間體化合物
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
US8476270B2 (en) 2009-09-14 2013-07-02 Gilead Sciences, Inc. Dihydropyrido[4,3-b]pyrazine-3-ones as modulators of toll-like receptors
JP5885670B2 (ja) 2009-12-11 2016-03-15 アルデイラ セラピューティクス， インコーポレイテッド 黄斑変性の処置のための組成物および方法
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6514114B2 (ja) 2013-01-23 2019-05-15 アルデイラ セラピューティクス， インコーポレイテッド 毒性アルデヒド関連疾患および処置
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
PL3663296T3 (pl) * 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
UY36298A (es) 2014-09-16 2016-04-29 Gilead Science Inc Formas sólidas de un modulador del receptor tipo toll
BR112017005100A2 (pt) 2014-09-16 2017-12-05 Gilead Sciences Inc métodos de preparação de moduladores de receptores do tipo toll
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2017035077A1 (en) 2015-08-21 2017-03-02 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
RU2743424C2 (ru) 2016-02-12 2021-02-18 Астеллас Фарма Инк. Производные тетрагидроизохинолина
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3694500A4 (en) * 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
US12006298B2 (en) 2018-08-06 2024-06-11 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
WO2020068986A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
JP7706758B2 (ja) 2019-03-26 2025-07-14 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
EP3962894A4 (en) 2019-05-02 2023-01-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND USES THEREOF
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4149470A4 (en) 2020-05-13 2024-04-24 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2022261160A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US5063245A (en) 1990-03-28 1991-11-05 Nova Pharmaceutical Corporation Corticotropin-releasing factor antagonism compounds
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CZ286892B6 (en) * 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW530047B (en) * 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
PL181895B1 (pl) * 1994-06-16 2001-10-31 Pfizer Nowe pirazolo-i pirolopirydyny _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ PL PL PL PL
JP2898887B2 (ja) * 1994-08-31 1999-06-02 沖電気工業株式会社 Ｉｃカードの読み取り装置
EP0729758A3 (en) * 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6020492A (en) * 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
EP0778277B1 (en) * 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
CZ244598A3 (cs) 1996-02-07 1998-10-14 Janssen Pharmaceutica N.V. Pyrazolopyrimidiny jako antagonisty CRF receptoru
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same

Also Published As

Publication number Publication date
AP1096A (en) 2002-08-26
IS4948A (is) 1999-01-19
NO313293B1 (no) 2002-09-09
AU3356397A (en) 1998-02-25
PE97098A1 (es) 1999-01-12
EA199900083A1 (ru) 1999-08-26
AU709203B2 (en) 1999-08-26
CA2262692A1 (en) 1998-02-12
TNSN97135A1 (fr) 2005-03-15
MA24296A1 (fr) 1998-04-01
DK0920429T3 (da) 2003-05-12
UY24655A1 (es) 2000-09-29
ID17980A (id) 1998-02-12
HRP970432A2 (en) 1998-08-31
TR199900228T2 (xx) 1999-03-22
WO1998005661A1 (en) 1998-02-12
CN1227552A (zh) 1999-09-01
CN1093130C (zh) 2002-10-23
NO990544D0 (no) 1999-02-05
NO990544L (no) 1999-03-31
EP0920429B1 (en) 2003-02-19
AR008829A1 (es) 2000-02-23
NZ333727A (en) 2000-09-29
OA10970A (en) 2001-11-05
JP2000501116A (ja) 2000-02-02
CA2262692C (en) 2002-06-11
YU5399A (sh) 2002-03-18
BG103143A (en) 1999-09-30
TW550265B (en) 2003-09-01
GT199700089A (es) 1999-01-26
KR20000029843A (ko) 2000-05-25
PL331602A1 (en) 1999-08-02
DE69719193D1 (de) 2003-03-27
DZ2289A1 (fr) 2002-12-25
US6492520B1 (en) 2002-12-10
BR9710808A (pt) 1999-08-17
CZ41199A3 (cs) 2000-01-12
DE69719193T2 (de) 2003-09-25
SK14099A3 (en) 2000-05-16
HRP970432B1 (en) 2002-10-31
EP0920429A1 (en) 1999-06-09
CZ292806B6 (cs) 2003-12-17
IL128188A0 (en) 1999-11-30
HK1021734A1 (en) 2000-06-30
AP9701052A0 (en) 1997-10-31
SA97180334A (ar) 2005-12-03
EA003188B1 (ru) 2003-02-27
ZA976954B (en) 1999-02-05
JP3345021B2 (ja) 2002-11-18
CO4900060A1 (es) 2000-03-27
ES2191183T3 (es) 2003-09-01
ATE232863T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
PA8435201A1 (es) Derivados 6,6- o 6,7-biciclicos sustituidos que contienen pirido o pirimido.
PA8436201A1 (es) Derivados 6,5-heterobiciclicos sustituidos
CO4930259A1 (es) Derivados 6,6-heterobiciclicos sustituidos y composiciones farmaceuticas que los contienen
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
AR038434A2 (es) Compuesto 14,15-dihidro-16-oxoparahercuamida y compuestos 2-desoxo de parahercuamida y marcfortina
HN1998000036A (es) Compuesto de pirazina
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
MX9201419A (es) Derivados de benzo isoxazol-piperidina.
EA199700061A1 (ru) Способ получения силденафила
PA8521701A1 (es) Derivados de pirazol
HN1998000011A (es) Derivados de acidos arilsulfonilaminohidroxamicos
HN1997000126A (es) Derivados de indazol
DK1193270T3 (da) Pyrrolobenzodiazepiner
GT199700052A (es) Sales metanosulfonatode5-(2-4-(1,2-benzoisotiazol-3-il)-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-onadihidratadas
GT199900040A (es) Biciclo [2.2.1] heptanos y compuestos relacionados.
EA199900373A2 (ru) Фармацевтические композиции
MA26932A1 (fr) Derives d'imidazole.
HN1997000146A (es) Derivados de pirimidina biciclica condensada
EP0957924A4 (en) PARTICULAR PHOSPHINYL DERIVATIVES USED AS NAALDASE INHIBITORS
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
NO20010331L (no) Ftalazinderivater som fosfodiesterase 4-inhibitorer
ATE209627T1 (de) Schlüsselzwischenprodukte zur herstellung von simvastatin
BR0114379A (pt) Derivados de c-ciclohexilmetilamina substituìdos
ES2143233T3 (es) Bascula para establecimientos de venta.
ES2151977T3 (es) Inhibidores de accion doble que contienen 1,2-diazepina.